Results 91 to 100 of about 28,888 (167)

Hyperlipidemia and associated risk factors among people living with HIV on antiretroviral therapy: a retrospective cohort study from Eastern China. [PDF]

Prev Med Rep
Cheng W, Zhang Y, Yang J, Jiang J, Pan X, Chai C, Wang Y.   +6 more
europepmc   +1 more source

Metabolic syndrome and its risk factors among adults living with HIV receiving antiretroviral therapy in Zambia: an ambidirectional cohort study. [PDF]

Sci Rep
Hamooya BM, Bosomprah S, Masenga SK, Mutengo KH, Cheelo C, Siame L, Simushi P, Mwakyoma T, Mudenda J, Mutale W, Halwiindi H, Bedimo R, Shrestha S, Chanda C, Heimburger DC, Lipworth L.   +15 more
europepmc   +1 more source

Comparable efficacy of bictegravir/emtricitabine/tenofovir alafenamide and doravirine/lamivudine/tenofovir disoproxil fumarate in therapy-naive Human Immunodeficiency Virus adults with very high baseline viraemia. [PDF]

J Med Microbiol
Calza L, Giglia M, Rigamonti C, Zuppiroli A, Marzolla D, Bon I, Viale P.   +6 more
europepmc   +1 more source

Lamivudine resistance in untreated chronic hepatitis B patients in Turkey

The Turkish Journal of Gastroenterology, 2008
Semra TUNÇBİLEK, Şükran KÖSE, Ahmet ELALDI, Sezin AKMAN   +3 more
doaj  

Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model. [PDF]

J Antimicrob Chemother
Collins LB, Le A, Nicol MR.
europepmc   +1 more source

Combined tenofovir, lamivudine, and dolutegravir treatment increases leptin and FABP4 expression in human subcutaneous adipose tissue. [PDF]

Einstein (Sao Paulo)
Zanardo LW, Izabel LDS, Hamada LM, Carvalho MB, Silva PAGOE, Joaquim HDG, Santoro S, Festuccia WT, Magdalon J.   +8 more
europepmc   +1 more source

The Epidemiology of HIV-1 Resistance to Two-Drug Regimens in Multicenter Cohort From Poland-A Cross-Sectional Study. [PDF]

Health Sci Rep
Załęski A, Lembas A, Osińska J, Dyda T, Suchacz M, Stempkowska-Rejek J, Orzechowska J, Wiercińska-Drapało A.   +7 more
europepmc   +1 more source

Comparative effectiveness of dolutegravir + lamivudine versus three-drug regimens in Swedish clinical practice: a nationwide study. [PDF]

J Int AIDS Soc
Sörstedt E, Nduva G, Månsson F, Mellgren Å, Repits J, Fernvik E, Stubbs A, Schroeder M, Brännström J, Carlander C.   +9 more
europepmc   +1 more source

Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials. [PDF]

Open Forum Infect Dis
Post FA, Wohl D, Liegeon G, Brar I, Hagins D, Yazdanpanah Y, Avihingsanon A, Liu H, Aizen K, Hindman JT, Gupta S.   +10 more
europepmc   +1 more source

Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis. [PDF]

J Comp Eff Res
Curteis T, Eddowes LA, Karlsson A, Luedke H, Rubinstein M, Hempfling M, Gurney J, Gandhi-Patel B, Unger N, Mordi U, Chen M, Jarrett J, Sherman EM, Mounzer K, Khalsa AM, Dinges WL, McKellar MS, Lipps A.   +17 more
europepmc   +1 more source